Skip to content

Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk

Home-based Exercise for Management of HIV-associated Cardiovascular Disease

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01377064
Enrollment
60
Registered
2011-06-20
Start date
2011-03-31
Completion date
2013-07-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Hyperlipidemia, Obesity

Keywords

HIV, physical activity, cardiovascular disease risk

Brief summary

Because of advances in drug treatment, people living with HIV/AIDS (PLWHA) are living longer, but are also at greater risk for cardiovascular disease (CVD) and diabetes. Exercise and increased physical activity can reduce the risk factors for these diseases in PLWHA, but no studies have tested an at-home exercise program that would benefit low income people and others who do not have access to exercise facilities. This study will test the feasibility of an at-home exercise program for PLWHA and prepare for a full-scale intervention study, which may lead to a reduction in CVD risk among PLWHA.

Interventions

9 months of home based physical activity meeting HHS recommendations for physical activity for all americans

No intervention, the group will be followed under their standard medical care.

Sponsors

National Institute of Nursing Research (NINR)
CollaboratorNIH
University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years and older * Medical diagnosis of HIV-1 positive serostatus * Sedentary lifestyle: not actively exercising ≥ 3 d•wk-1 for 20 min per session * 18.5 kg/m2 \< BMI \< 40.0 kg/m2 * Stable, DHHS-approved ART regimen for previous 3 months, with HIV viral load below 75 copies/mL * Capable of performing the required exercise regimen * Have daily access to a telephone for approximately 10 months * Capacity and willingness to provide informed consent and accept randomized group assignment

Exclusion criteria

* Individuals who have a clinical history strongly suggestive of Type 1 diabetes. * History of serious arrythmias, cardiomyopathy, congestive heart failure, stroke or transient ischemic cerebral attacks, peripheral vascular disease with intermittent claudication, myocardial infarction, or CABG. * Malignancies in the past 5 years, except therapeutically controlled skin cancer. * Plans to be away \> 4 weeks in the next 9 months * Score of 5 or greater on the DAST or MAST (signifying excessive use of drugs or alcohol). * Weight loss in excess of 10% body weight in previous 12 weeks. * Chronic or recurrent respiratory, gastrointestinal, neuromuscular, neurological, or psychiatric conditions. * Inflammatory-related conditions such as collagen disorders. * Any other medical condition or disease that is life-threatening or that can interfere with or be aggravated by exercise.

Design outcomes

Primary

MeasureTime frameDescription
Amount of Physical Activity9 monthsAccelerometer data will be the primary means of determining the participants' physical activity levels. Participants will be instructed to wear the accelerometer at baseline, 4 months, and 9 months. The participants will be required to wear the accelerometer during the waking hours for seven consecutive days. Data from participants with at least four days and at least 10 hours per day will be included.

Secondary

MeasureTime frameDescription
Cardiorespiratory Fitness9 monthsEach participant will complete a graded exercise stress test (GXT) with indirect calorimetry. This test will be used to screen for abnormal physiological responses to exercise and for determining the participant's maximal ability to utilize oxygen (an index of cardiorespiratory fitness).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026